Cargando…

Evaluation of the Efficacy of Doxycycline, Ciprofloxacin, Levofloxacin, and Co-trimoxazole Using In Vitro and In Vivo Models of Q Fever

Q fever, caused by the intracellular pathogen Coxiella burnetii, is traditionally treated using tetracycline antibiotics, such as doxycycline. Doxycycline is often poorly tolerated, and antibiotic-resistant strains have been isolated. In this study, we have evaluated a panel of antibiotics (doxycycl...

Descripción completa

Detalles Bibliográficos
Autores principales: Clay, K. A., Hartley, M. G., Armstrong, S., Bewley, K. R., Godwin, K., Rayner, E., Vipond, J., Bailey, M., Atkins, T. P., Norville, I. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522727/
https://www.ncbi.nlm.nih.gov/pubmed/34370577
http://dx.doi.org/10.1128/AAC.00673-21
_version_ 1784585150008393728
author Clay, K. A.
Hartley, M. G.
Armstrong, S.
Bewley, K. R.
Godwin, K.
Rayner, E.
Vipond, J.
Bailey, M.
Atkins, T. P.
Norville, I. H.
author_facet Clay, K. A.
Hartley, M. G.
Armstrong, S.
Bewley, K. R.
Godwin, K.
Rayner, E.
Vipond, J.
Bailey, M.
Atkins, T. P.
Norville, I. H.
author_sort Clay, K. A.
collection PubMed
description Q fever, caused by the intracellular pathogen Coxiella burnetii, is traditionally treated using tetracycline antibiotics, such as doxycycline. Doxycycline is often poorly tolerated, and antibiotic-resistant strains have been isolated. In this study, we have evaluated a panel of antibiotics (doxycycline, ciprofloxacin, levofloxacin, and co-trimoxazole) against C. burnetii using in vitro methods (determination of MIC using liquid and solid media; efficacy assessment in a THP cell infection model) and in vivo methods (wax moth larvae and mouse models of infection). In addition, the schedule for antibiotic treatment has been evaluated, with therapy initiated at 24 h pre- or postchallenge. Both doxycycline and levofloxacin limited overt clinical signs during treatment in the AJ mouse model of aerosol infection, but further studies are required to investigate the possibility of disease relapse or incomplete bacterial clearance after the antibiotics are stopped. Levofloxacin was well tolerated and therefore warrants further investigation as an alternative to the current recommended treatment with doxycycline.
format Online
Article
Text
id pubmed-8522727
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-85227272021-10-20 Evaluation of the Efficacy of Doxycycline, Ciprofloxacin, Levofloxacin, and Co-trimoxazole Using In Vitro and In Vivo Models of Q Fever Clay, K. A. Hartley, M. G. Armstrong, S. Bewley, K. R. Godwin, K. Rayner, E. Vipond, J. Bailey, M. Atkins, T. P. Norville, I. H. Antimicrob Agents Chemother Experimental Therapeutics Q fever, caused by the intracellular pathogen Coxiella burnetii, is traditionally treated using tetracycline antibiotics, such as doxycycline. Doxycycline is often poorly tolerated, and antibiotic-resistant strains have been isolated. In this study, we have evaluated a panel of antibiotics (doxycycline, ciprofloxacin, levofloxacin, and co-trimoxazole) against C. burnetii using in vitro methods (determination of MIC using liquid and solid media; efficacy assessment in a THP cell infection model) and in vivo methods (wax moth larvae and mouse models of infection). In addition, the schedule for antibiotic treatment has been evaluated, with therapy initiated at 24 h pre- or postchallenge. Both doxycycline and levofloxacin limited overt clinical signs during treatment in the AJ mouse model of aerosol infection, but further studies are required to investigate the possibility of disease relapse or incomplete bacterial clearance after the antibiotics are stopped. Levofloxacin was well tolerated and therefore warrants further investigation as an alternative to the current recommended treatment with doxycycline. American Society for Microbiology 2021-10-18 /pmc/articles/PMC8522727/ /pubmed/34370577 http://dx.doi.org/10.1128/AAC.00673-21 Text en © Crown copyright 2021. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Experimental Therapeutics
Clay, K. A.
Hartley, M. G.
Armstrong, S.
Bewley, K. R.
Godwin, K.
Rayner, E.
Vipond, J.
Bailey, M.
Atkins, T. P.
Norville, I. H.
Evaluation of the Efficacy of Doxycycline, Ciprofloxacin, Levofloxacin, and Co-trimoxazole Using In Vitro and In Vivo Models of Q Fever
title Evaluation of the Efficacy of Doxycycline, Ciprofloxacin, Levofloxacin, and Co-trimoxazole Using In Vitro and In Vivo Models of Q Fever
title_full Evaluation of the Efficacy of Doxycycline, Ciprofloxacin, Levofloxacin, and Co-trimoxazole Using In Vitro and In Vivo Models of Q Fever
title_fullStr Evaluation of the Efficacy of Doxycycline, Ciprofloxacin, Levofloxacin, and Co-trimoxazole Using In Vitro and In Vivo Models of Q Fever
title_full_unstemmed Evaluation of the Efficacy of Doxycycline, Ciprofloxacin, Levofloxacin, and Co-trimoxazole Using In Vitro and In Vivo Models of Q Fever
title_short Evaluation of the Efficacy of Doxycycline, Ciprofloxacin, Levofloxacin, and Co-trimoxazole Using In Vitro and In Vivo Models of Q Fever
title_sort evaluation of the efficacy of doxycycline, ciprofloxacin, levofloxacin, and co-trimoxazole using in vitro and in vivo models of q fever
topic Experimental Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522727/
https://www.ncbi.nlm.nih.gov/pubmed/34370577
http://dx.doi.org/10.1128/AAC.00673-21
work_keys_str_mv AT clayka evaluationoftheefficacyofdoxycyclineciprofloxacinlevofloxacinandcotrimoxazoleusinginvitroandinvivomodelsofqfever
AT hartleymg evaluationoftheefficacyofdoxycyclineciprofloxacinlevofloxacinandcotrimoxazoleusinginvitroandinvivomodelsofqfever
AT armstrongs evaluationoftheefficacyofdoxycyclineciprofloxacinlevofloxacinandcotrimoxazoleusinginvitroandinvivomodelsofqfever
AT bewleykr evaluationoftheefficacyofdoxycyclineciprofloxacinlevofloxacinandcotrimoxazoleusinginvitroandinvivomodelsofqfever
AT godwink evaluationoftheefficacyofdoxycyclineciprofloxacinlevofloxacinandcotrimoxazoleusinginvitroandinvivomodelsofqfever
AT raynere evaluationoftheefficacyofdoxycyclineciprofloxacinlevofloxacinandcotrimoxazoleusinginvitroandinvivomodelsofqfever
AT vipondj evaluationoftheefficacyofdoxycyclineciprofloxacinlevofloxacinandcotrimoxazoleusinginvitroandinvivomodelsofqfever
AT baileym evaluationoftheefficacyofdoxycyclineciprofloxacinlevofloxacinandcotrimoxazoleusinginvitroandinvivomodelsofqfever
AT atkinstp evaluationoftheefficacyofdoxycyclineciprofloxacinlevofloxacinandcotrimoxazoleusinginvitroandinvivomodelsofqfever
AT norvilleih evaluationoftheefficacyofdoxycyclineciprofloxacinlevofloxacinandcotrimoxazoleusinginvitroandinvivomodelsofqfever